货号:A487798
同义名:
头孢曲松钠水合物
/ Ro 13-9904 sodium hydrate; Ceftriaxone(sodium salt hydrate)
Ceftriaxone sodium hydrate 是一种广谱 β-内酰胺类三代头孢菌素,对革兰氏阴性及阳性菌均具良好抗菌活性;同时是 GSK3β 共价抑制剂(IC50 0.78 μM)和 Aurora B 抑制剂,兼具抗炎、抗肿瘤及抗氧化活性,常用于细菌性感染与脑膜炎的研究。
HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | Ceftriaxone sodium (trihydrate), one of the beta-lactam antibiotics, is a third-generation semi-synthetic antibiotic belonging to the class of cephalosporins. It has bactericidal action; its main activity is related to the Gram-negative bacteria, being also able to act against Gram-negative bacilli resistant to the first- and second-generation cephalosporins[2]. Ceftriaxone is a stimulator of EAAT2 (Excitatory amino acid transporter2) expression with neuroprotective effects in both in vitro and in vivo models based in part on its ability to inhibit neuronal cell death by glutamate excitotoxicity[3]. Long term ceftriaxone sodium administration resulted in gut microbiota dysbiosis, intestine histological lesions, growth inhibition, spleen index reducing. Not only the immune defense, long term ceftriaxone administration also affected immune regulation[4]. |
| Concentration | Treated Time | Description | References | |
| THP-1 monocytes | 4 mg/L | 7 days | Evaluated the bactericidal effect of ceftriaxone on intracellular MAC, showing EC50 of 0.20-0.25 times MIC and maximal kill of 1.16-1.96 log10 CFU/mL. | J Infect Dis. 2024 Aug 16;230(2):e230-e240. |
| Administration | Dosage | Frequency | Description | References | ||
| Male Sprague Dawley rats | Cocaine self-administration followed by abstinence model | Intraperitoneal injection | 100 and 200 mg/kg | Once daily for 6 days | To investigate the effects of ceftriaxone on context-primed relapse following abstinence and its impact on AMPA receptor subunit expression in the NAc. Results showed that both doses of ceftriaxone attenuated relapse and reduced GluA1 expression in the NAc, but did not affect GluA2 expression. | Eur Neuropsychopharmacol. 2016 Feb;26(2):186-194 |
| Sprague-Dawley rats | 6-hydroxydopamine (6-OHDA) Parkinson’s disease model | Intraperitoneal injection | 200 mg/kg | Seven consecutive daily injections | Ceftriaxone increased GLT-1 expression and glutamate uptake, reduced tyrosine hydroxylase (TH) loss induced by 6-OHDA, and decreased amphetamine-induced rotation behavior. | Mol Neurobiol. 2014 Jun;49(3):1282-92 |
| Sprague-Dawley rats | Subcutaneous injection model | Subcutaneous injection | 1000 mg/kg | Once daily for 12 days | To evaluate the local tolerability of subcutaneous ceftriaxone administration. Results showed that the local tissue response was remarkably reduced when the same ceftriaxone dose was given at a lower concentration (25 mg/ml) over a longer period of time (120 min). | Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02090-19 |
| Swiss albino mice | Cecal ligation and puncture (CLP)-induced sepsis model | Subcutaneous injection | 100 mg/kg | Single dose, 3 hours post-CLP | To evaluate the protective effect of ceftriaxone in a sepsis model, results showed that ceftriaxone alone reduced bacterial load but did not significantly improve survival. | Inflammation. 2020 Jun;43(3):1035-1043 |
| Mice | Tsc1GFAPCKO mouse model | Intraperitoneal injection | 200 mg/kg | Daily until death or the pre-defined endpoint of the experiment | Early treatment (before seizure onset) increased astrocyte glutamate transporter expression, decreased extracellular glutamate levels, neuronal death, and seizure frequency, and improved survival; late treatment (after seizure onset) increased glutamate transporter expression but had no effect on seizures. | Neurobiol Dis. 2010 Mar;37(3):764-71 |
| Mice | Epilepsy model | Intraperitoneal injection | 200 mg/kg | Daily | Evaluate the antiepileptic effect of ceftriaxone in epilepsy models | J Exp Med. 2017 Feb;214(2):547-563 |
| Mice | Pneumococcal meningitis model | Intraperitoneal | 100 mg/kg | Daily starting from 16 hours after infection | To evaluate the therapeutic effect of ceftriaxone on pneumococcal meningitis, results showed no significant difference in mortality between the ceftriaxone-treated group and the placebo group. | J Neuroinflammation. 2019 Dec 28;16(1):279 |
| BALB/c mice | Systemic lupus erythematosus model | Oral gavage | 400 mg/kg | Once daily for 5 consecutive days | To reduce pre-existing bacteria populations to boost the proliferation of intestinal microorganisms from donor animals post-FMT | Antioxidants (Basel). 2021 Sep 7;10(9):1426 |
| BALB/c mice | Vaginal infection model | Intraperitoneal | 15 mg/kg | Single dose | To evaluate the therapeutic effect of ceftriaxone on vaginal infection in mice, results showed all mice cleared the infection within 24 hours after treatment. | Int J Antimicrob Agents. 2016 Oct;48(4):367-72 |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00002052 | HIV Infections ... 展开 >> Salmonella Infections 收起 << | Not Applicable | Completed | - | United States, California ... 展开 >> Los Angeles County - USC Med Ctr Los Angeles, California, United States, 90033 收起 << |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.38mL 0.28mL 0.14mL |
6.90mL 1.38mL 0.69mL |
13.80mL 2.76mL 1.38mL |
|
| CAS号 | 104376-79-6 |
| 分子式 | C18H30N8Na2O14S3 |
| 分子量 | 724.65 |
| SMILES Code | CN1C(SCC(CS[C@]2([H])[C@@](/N=C([O-])/C(C3=CSC(N)=N3)=N\OC)([H])C4=O)=C(N42)C([O-])=O)=NC(C(N1)=O)=O.[H]O[H].[H]O[H].[H]O[H].[H]O[H].[H]O[H].[H]O[H].[H]O[H].[Na+].[Na+] |
| MDL No. | MFCD01750405 |
| 别名 | 头孢曲松钠水合物 ;Ro 13-9904 sodium hydrate; Ceftriaxone(sodium salt hydrate); Rosihlitazone; Ro 13-9904; Ceftriaxone disodium hemiheptahydrate; heptahydrate; Ceftriaxone disodium salt hemi |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, 2-8°C |
沪公网安备 31011702889066号
沪ICP备2024050318号-1